Janumet

Metformin Hydrochloride and Sitagliptin, the active ingredient in Janumet, is a biguanide/DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to control blood glucose levels when combined with diet and exercise.

GNH USA supplies Janumet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Janumet is used in the treatment of type 2 diabetes mellitus, a chronic metabolic disorder characterized by elevated blood glucose. - Type 2 diabetes mellitus: improves glycemic control as part of combination therapy with diet and exercise. - Inadequate control on metformin alone: provides additional glucose lowering when added to existing metformin therapy. - Patients requiring dual‑mechanism therapy: combines insulin sensitization and incretin enhancement to reduce HbA1c.

Janumet may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion. - Mild hypoglycemia: especially when used with sulfonylureas or insulin.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe hypoglycemia: marked confusion, loss of consciousness. - Allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: jaundice or abnormal liver tests.

Before initiating Janumet, several safety considerations should be reviewed. - Renal function assessment: evaluate eGFR and avoid use in severe renal impairment. - Hepatic function monitoring: check liver enzymes periodically. - Risk of lactic acidosis: discontinue before any iodinated contrast procedures. - Use caution in elderly: dose adjustments may be required. - Avoid in pregnancy and lactation unless benefits outweigh risks. - Store at room temperature: keep in the original container, protect from moisture and heat.

Janumet can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate metformin‑associated lactic acidosis; hold metformin before and after exposure. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): increase sitagliptin plasma concentrations. - Insulin or sulfonylureas: heightened risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Diuretics: may reduce renal clearance, necessitating renal function monitoring. - ACE inhibitors or ARBs: combined effect on renal function warrants observation. - Alcohol: can potentiate metformin‑related lactic acidosis. - Rifampin: may lower sitagliptin levels, reducing efficacy.